Data & Images
|Product Name||Anti-PCSK9 Antibody|
|Description||Rabbit IgG polyclonal antibody for Proprotein convertase subtilisin/kexin type 9(PCSK9) detection. Tested with WB, IHC-P in Human.|
|Cite This Product||Anti-PCSK9 Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # PA2130)|
|Replacement Item||This antibody may replace the following items: sc-34696|sc-66996|sc-34698|sc-34694|sc-34691|sc-34693|sc-34692|sc-515082 from Santa Cruz Biotechnology.|
*Our Boster Guarantee covers the use of this product in the above tested applications.
**For positive and negative control design, consult "Tissue specificity" under Protein Target Info.
|Recommended Detection Systems||Boster recommends Enhanced Chemiluminescent Kit with anti-Rabbit IgG (EK1002) for Western blot, and HRP Conjugated anti-Rabbit IgG Super Vision Assay Kit (SV0002-1) for IHC(P).
*Blocking peptide can be purchased at $50. Contact us for more information
**Boster also offers various secondary antibodies for Immunoflourescecne and IHC. Take advantage of the buy 1 primary antibody get 1 secondary antibody for free promotion for the entire year 2017!
|Immunogen||A synthetic peptide corresponding to a sequence at the C-terminus of human PCSK9(671-687aa AVTAVAICCRSRHLAQA).|
|Cross Reactivity||No cross reactivity with other proteins|
|Contents||Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.
*carrier free antibody available upon request.
|Concentration||Add 0.2ml of distilled water will yield a concentration of 500ug/ml.|
|Storage||At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time.Avoid repeated freezing and thawing.|
|Purification||Immunogen affinity purified.|
Protein Target Info (Source: Uniprot.org)
You can check the tissue specificity below for information on selecting positive and negative control.
|Protein Name||Proprotein convertase subtilisin/kexin type 9|
|Molecular Weight||74286 MW|
|Protein Function||Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non- acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)- mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. .|
|Tissue Specificity||Expressed in neuro-epithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells.|
|Sequence Similarities||Belongs to the peptidase S8 family.|
|Subcellular Localization||Cytoplasm. Secreted. Endosome. Lysosome. Cell surface. Endoplasmic reticulum. Golgi apparatus. Autocatalytic cleavage is required to transport it from the endoplasmic reticulum to the Golgi apparatus and for the secretion of the mature protein. Localizes to the endoplasmic reticulum in the absence of LDLR and colocalizes to the cell surface and to the endosomes/lysosomes in the presence of LDLR. The sorting to the cell surface and endosomes is required in order to fully promote LDLR degradation.|
|Alternative Names||Proprotein convertase subtilisin/kexin type 9;3.4.21.-;Neural apoptosis-regulated convertase 1;NARC-1;Proprotein convertase 9;PC9;Subtilisin/kexin-like protease PC9;PCSK9;NARC1;PSEC0052;|
|Research Areas|||signal transduction|metabolism|amino acids| cardiovascular|lipids / lipoproteins|lipid metabolism|cholesterol metabolism| stem cells|neural stem cells|intracellular| signal transduction| cell biology|proteolysis / ubiquitin|proteolytic enzymes|serine protease|proprotein convertases| metabolism|pathways and processes|metabolic signaling pathways|lipid and lipoprotein metabolism|amino acid metabolism|types of disease|cancer||
Background for Proprotein convertase subtilisin/kexin type 9
Dilution Ratios/Recommended Concentrations
At Boster we strive to provide the best Anti-PCSK9 Antibody by testing all applications on non-spiked tissues and cell lines to ensure that the affinity of the antibody is enough to react to the endogenouse level of the target protein. Read more about our QC panel here.
|Recommended dilution ratios are listed below:|
Immunohistochemistry(Paraffin-embedded Section), 0.5-1μg/ml, Human, By Heat|
Western blot, 0.1-0.5μg/ml, Human
**Boster provides high sensitivity secondary antibody kits for Western blotting and IHC. For more info see Related Products below.
Anti-PCSK9 Antibody Images
Click the images to enlarge.
All lanes: Anti PCSK9 (PA2130) at 0.5ug/ml
Lane 1: A549 Whole Cell Lysate at 40ug
Lane 2: HELA Whole Cell Lysate at 40ug
Lane 3: U87 Whole Cell Lysate at 40ug
Lane 4: PANC Whole Cell Lysate at 40ug
Predicted bind size: 74KD
Observed bind size: 74KD
IHC(P): Human Intestinal Cancer Tissue
1. Post-translational modification:phosphorylation, methylation, glycosylation etc. These modifications prevent SDS molecules from binding to the target protein and thus make the band size appear larger than expected
2. Post-translational cleavage: this can cause smaller bands and or multiple bands
3. Alternative splicing: the same gene can have alternative splicing patterns generating different size proteins, all with reactivities to the antibody.
4. Amino Acid R chain charge: SDS binds to positive charges. The different size and charge of the Amino Acid side chains can affect the amount of SDS binding and thus affect the observed band size.
5. Multimers: Multimers are usually broken up in reducing conditions. However if the interactions between the multimers are strong, the band may appear higher.,